Table 2.

Association between BMI and hormones/peptides (mean ±SE) among a sample of 710 women with breast cancer

BMI < 25 (n = 284)BMI = 25-29.9 (n = 216)BMI > 30 (n = 210)P for trend
C-peptide (ng/mL)
    Unadjusted1.83 ± 0.062.37 ± 0.07*2.82 ± 0.07,0.0001
    Adjusted§1.79 ± 0.062.34 ± 0.06*2.91 ± 0.07,0.0001
    Adjusted1.81 ± 0.062.34 ± 0.06*2.88 ± 0.07,0.0001
Leptin (ng/mL)
    Unadjusted12.5 ± 0.823.5 ± 0.9*42.2 ± 0.9,0.0001
    Adjusted§12.8 ± 0.823.6 ± 0.9*41.6 ± 0.9,0.0001
    Adjusted13.0 ± 0.823.7 ± 0.9*41.3 ± 0.9,0.0001
IGF-I (ng/mL)
    Unadjusted144.1 ± 3.4137.8 ± 3.9*114.9 ± 3.9,0.0001
    Adjusted§142.5 ± 3.1136.5 ± 3.5*118.4 ± 3.6,0.0001
    Adjusted142.3 ± 3.4136.5 ± 3.5*118.7 ± 3.6,0.0001
IGFBP-3 (μg/mL)
    Unadjusted4.09 ± 0.064.10 ± 0.074.04 ± 0.070.57
    Adjusted§4.10 ± 0.064.08 ± 0.064.05 ± 0.070.57
    Adjusted4.10 ± 0.064.08 ± 0.064.05 ± 0.070.60
IGF-I:IGFBP-3
    Unadjusted35.1 ± 0.733.6 ± 0.8*28.6 ± 0.8,0.0001
    Adjusted§34.7 ± 0.633.4 ± 0.7*29.4 ± 0.8,0.0001
    Adjusted34.7 ± 0.633.4 ± 0.8*29.4 ± 0.7,0.0001
  • * P < 0.05, BMI = 25-29.9 significantly different from BMI < 25.

  • P < 0.05, BMI > 30 significantly different from BMI < 25.

  • P < 0.05, BMI > 30 significantly different from BMI = 25.0-29.9.

  • § Adjusted for study site, age, ethnicity, education, menopausal status, disease stage, adjuvant treatment, tamoxifen use, type 2 diabetes, and smoking status.

  • Adjusted for all the above covariates, including sports/recreational MET-hours per week.